菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

8th Halle Conference on Recombinant Proteins
March 12-13, 2026 | Deutsche Akademie der Naturforscher Leopoldina, Halle, Germany
 

Overview

 

The 8th Halle Conference on Recombinant Proteins (HC8) is a scientific forum uniting expert from academia and industry to discuss advances in recombinant protein research, production, characterization, and application across biopharmaceuticals and therapeutics.

 

WuXi Biologics CRO Services empowers antibody and protein research with extensive drug development expertise and end-to-end capabilities including antibody discovery, lead optimization, high-throughput to gram-scale protein expression, purification, early developability assessment, and functional characterization. Our one-stop, modular services help streamline biologics drug discovery and research, accelerating progression toward downstream development readiness.

 

Live Presentation

Pioneering BsAb Production with High-Throughput Platforms and Fit-for-Need Analytical Solutions

Session Time: 9:30 AM (local time), Friday, March 13, 2026

Abstract: Production of bsAbs remains challenging, especially for bsAbs with two distinct light chains, as chain mispairing constrains throughput, yield, and purity. We introduce Quick ‘n’ Clean, an HTP platform for producing diverse bsAb formats, automating steps from expression to purification. The platform rapidly generates bsAbs in both double-tag and tagless formats with high purity and yield. Tagless bsAbs suit ADC conjugation, in vitro assays, and in vivo studies. Quick ‘n’ Clean enables rapid optimal pairing screening and streamlines downstream workflows, establishing a next-gen platform for bsAb R&D.

Speaker: Winfried Elis, Ph.D., Senior Manager, Business Development, CRO Services. Winfried studied biology in Freiburg, Germany, and at the University of Michigan, USA, graduating with a diploma (2000) and M.S. (1998), respectively. He received his Ph.D. from the University of Freiburg in 2004, working at the local Max-Planck Institute for Immunobiology on signal transduction in immune cells. Thereafter, he joined Novartis in Cambridge, USA, as a postdoc, working on drug target identification, primarily in oncology. In 2008, he returned to Germany to start as a scientist at MorphoSys in Munich, working on the identification of fully human therapeutic antibodies, during which time he became a co-inventor on two patents (anti-Her3 and anti-C5aR antibodies).

Request a Meeting

Featured Posters

Poster
High-Throughput Developability Assessment for Early-Stage Lead Optimization
Session Time: March 12-13, 2026

Poster
Bispecific Antibody Discovery: From Strategic Design to Fit-for-Purpose Screening & Characterization
March 12-13, 2026